Aktuellt
SENASTE
Redeye maintains its positive view and reiterates our Base Case of SEK 42 per share. The announced Veterans Affairs Federal Supply Schedule contract for deprexis® in the US, an evidence-based digital therapy for the treatment of symptoms of depression, is an important milestone in Orexo’s advancements in the commercialization of the company’s digital therapies.
LÄS MER
